HeartBeam, Inc. — Form 8-K Summary
Business Context and Reporting Period
HeartBeam filed a current report under Sections 13 and 15(d) of the Exchange Act. The earliest reported events occurred on August 2, 2022; the report was signed on August 5, 2022. The filing does not report quarterly or annual financial results. HeartBeam develops digital health and cardiac monitoring solutions and trades under BEAT and BEATW on Nasdaq.
Material Agreements and Financial Terms
- LIVMOR supplemental agreement: HeartBeam agreed to pay an additional $200,000 for access to source materials and code associated with a Company-branded version of LIVMOR’s FDA-cleared Halo+ remote patient monitoring solution.
- The filing states that the $200,000 payment was made and that LIVMOR delivered copies of the source materials and code.
- Licenses granted by LIVMOR will automatically convert to non-exclusive, perpetual, royalty-free, and fully paid-up licenses.
- Chief Technical Officer appointment: Ken Persen was appointed effective August 2, 2022, under an employment agreement with an annual salary of $300,000, paid semi-monthly.
- Mr. Persen is eligible for an incentive bonus of up to 30% of annual base salary: 20% tied to delivery of complete telehealth software ready for FDA submission and 10% tied to overall corporate goals.
- Subject to Board or Compensation Committee approval, Mr. Persen is to receive an option to purchase 80,000 common shares. The exercise price was not specified because it will be determined when the option is granted.
Material Changes Versus the Prior Comparable Period
- The filing does not provide comparable-period financial statements or operating metrics.
- HeartBeam expanded its rights to LIVMOR technology through a $200,000 source-code payment and related perpetual, royalty-free license terms.
- The company added a Chief Technical Officer with responsibility relevant to telehealth software development and potential FDA submission preparation.
Guidance, Outlook, Risks, and Unusual Items
- The filing provides no formal revenue, earnings, cash-flow, liquidity, or operating guidance.
- The telehealth software delivery milestone and FDA-submission readiness are conditions for a portion of the CTO’s potential incentive bonus, but the filing does not provide a submission date or approval expectation.
- The source-code transaction may support development of a Company-branded remote patient monitoring offering, but the filing does not quantify expected revenue, commercialization timing, development costs, or regulatory risks.
- The option grant remains subject to approval, and its exercise price and other grant terms were not provided in the filing text.
- The filing states that there are no reportable related-party transactions involving Mr. Persen and no family relationship with current officers or directors.
Key Facts Investors Should Verify
- Verify the full Supplemental Agreement for the scope of the source-code rights, license limitations, delivery obligations, and termination provisions.
- Confirm whether the $200,000 payment was recorded as an expense, prepaid cost, intangible asset, or another accounting category in subsequent financial statements.
- Review the full employment agreement and any subsequent filing confirming approval, vesting, exercise price, and accounting treatment of the 80,000-share option.
- Monitor progress toward delivery of telehealth software ready for FDA submission and any subsequent regulatory filings or announcements.
- Assess future cash requirements associated with the $300,000 annual CTO salary, potential bonus, equity compensation, product development, and regulatory activities.